ReviewMolecular metabolism2021
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
Review in Molecular metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Clinical and laboratory characteristics of novel diabetes subgroups: A systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- A machine learning model for optimizing treatment of patients with poorly controlled type 2 diabetes.Communications medicine · 2026Article
- Aetiological clustering of newly diagnosed type 2 diabetes using machine learning: a retrospective cross-sectional study in Dubai, UAE.BMJ open · 2025Article
- Assessing Plasma C-Peptide Levels and Their Relationship with Health-Related Quality of Life in Patients with Prediabetes and Type 1 and Type 2 Diabetes.Biomedicines · 2025Article
- Appraisal of Clinical Explanatory Variables in Subtyping of Type 2 Diabetes Using Machine Learning Models.Journal of clinical medicine · 2025Article
- Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC.Scientific reports · 2025Article
- Relationship Between Glycosylated Hemoglobin and Serum Lipid Profile in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Analysis.Health science reports · 2025Article
- Evaluation of the efficacy of online healthcare system for the remote management of type 2 diabetes mellitus.Medicine · 2025Observational
- Adiponectin and Leptin-Considerations in Adult Patients with Spinal Muscular Atrophy Type 3.Diagnostics (Basel, Switzerland) · 2025Article
- New approach to optimize therapy in type 2 diabetes mellitus: the importance of subclassification.Frontiers in endocrinology · 2025Review
- Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety.Frontiers in medicine · 2025Review
- Linking extent of return to fasting state after oral glucose tolerance test to future risk of prediabetes and type 2 diabetes: Insights from the TLGS.Journal of diabetes investigation · 2024Article
- Current barriers to initiating insulin therapy in individuals with type 2 diabetes.Frontiers in endocrinology · 2024Review
- Surrogate indices of insulin resistance using the Matsuda index as reference in adult men-a computational approach.Frontiers in endocrinology · 2024Article
- Article
- A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis.International journal of environmental research and public health · 2022Article
- A novel diabetes typology: towards precision diabetology from pathogenesis to treatment.Diabetologia · 2022Review
- The antihyperglycemic effect of pulsed electric field-extracted polysaccharide ofFrontiers in nutrition · 2022Article
- Protein Intake, Metabolic Status and the Gut Microbiota in Different Ethnicities: Results from Two Independent Cohorts.Nutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes is a syndrome defined by hyperglycaemia that is the result of various degrees of pancreatic β-cell failure and reduced insulin sensitivity. Although diabetes can be caused by multiple metabolic dysfunctions, most patients are defined as having either type 1 or type 2 diabetes. Recently, Ahlqvist and colleagues proposed a new method of classifying patients with adult-onset diabetes, considering the heterogenous metabolic phenotype of the disease. This new classification system could be useful for more personalised treatment based on the underlying metabolic disruption of the disease, although to date no prospective intervention studies have generated data to support such a claim. SCOPE OF REVIEW: In this review, we first provide a short overview of the phenotype and pathogenesis of type 2 diabetes and discuss the current and new classification systems. We then review the effects of different anti-diabetic medication classes on insulin sensitivity and β-cell function and discuss future treatment strategies based on the subgroups proposed by Ahlqvist et al. MAJOR
conclusionsThe proposed novel type 2 diabetes subgroups provide an interesting concept that could lead to a better understanding of the pathophysiology of the broad group of type 2 diabetes, paving the way for personalised treatment choices based on understanding the root cause of the disease. We conclude that the novel subgroups of adult-onset diabetes would benefit from anti-diabetic medications that take into account the main pathophysiology of the disease and thereby prevent end-organ damage. However, we are only beginning to address the personalised treatment of type 2 diabetes, and studies investigating the effects of current and novel drugs in subgroups with different metabolic phenotypes are needed to develop personalised treatment of the syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.